Belzutifan available on the NHS for patients with VHL disease
We are delighted to announce that the National Institute for [...]
Multi-million-pound UK-wide research into cancer immunotherapy
The Francis Crick Institute and The Royal Marsden NHS Foundation [...]
Kidney Cancer Highlights from ESMO 2024
This year’s European Society for Medical Oncology (ESMO) Congress was [...]
Pazopanib plus bevacizumab shows promise as a first-line treatment for kidney cancer
Results from a phase 2 study of pazopanib alternated with [...]
89Zr-DFO-girentuximab for PET/CT imaging of kidney cancer
Researchers are looking for better ways to diagnose kidney cancer. Currently, diagnosis is [...]
Intermittent immunotherapy in patients with metastatic kidney cancer
The combination of ipilimumab/nivolumab is approved for patients as a [...]
Patient perspectives on reduced treatment schedules for immunotherapy
Immunotherapy has transformed the treatment of many cancers, including kidney [...]
Belzutifan compared to everolimus for advanced kidney cancer
People with kidney cancer have been shown to have changes (mutations) in [...]
FDA grant fast track status to CAR T cell therapy for kidney cancer
The Food and Drug Administration (FDA) in America has granted [...]
Perioperative nivolumab in intermediate/high risk kidney cancer patients
The standard of care for patients with intermediate/high risk kidney [...]
